BELLUS Health’s portfolio focuses on novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.

The Company’s lead drug candidate is BLU-5937 being developed for the treatment of chronic cough.

In November 2018, the Company announced positive top-line results from the clinical Phase 1 study for BLU-5937, in which BLU-5937 was shown to be safe and well tolerated. The benign side effect profile, in combination with the anti-tussive effect demonstrated in several preclinical studies, further reinforces the Company’s position that BLU-5937 has the potential to be a best-in-class therapeutic for refractory chronic cough patients. Based on the positive data from the Phase 1 study, BELLUS Health expects to initiate a clinical Phase 2 study for BLU-5937 in patients with refractory unexplained chronic cough in mid-2019, with top-line results anticipated in mid-2020. Refractory chronic cough is a significant unmet medical need with no currently approved treatments.


Share this

Sign up for email alerts

Email Address *
Enter the code shown above.